Genetic Study of Newly Diagnosed Central Nervous System Tumors in Young Children
Gene Expression Profiling of Infant Embryonal Central Nervous System Tumors by Microarray Gene Chip Analysis: Angiogenesis, Invasion and Metastasis
2 other identifiers
observational
83
1 country
9
Brief Summary
RATIONALE: Genetic studies may help in understanding the genetic processes involved in the development of some types of cancer. PURPOSE: Genetic study to learn more about genes involved in the development of central nervous system tumors in young children.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Mar 2001
9 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
February 2, 2001
CompletedStudy Start
First participant enrolled
March 1, 2001
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 1, 2003
CompletedStudy Completion
Last participant's last visit for all outcomes
March 1, 2003
CompletedFirst Posted
Study publicly available on registry
June 6, 2003
CompletedJuly 20, 2011
July 1, 2011
2 years
February 2, 2001
July 19, 2011
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Genes that are expressed in metastatic vs. non-metastatic tumors
Prior to therapy
Secondary Outcomes (1)
Protein expression of genes found to be expressed
Prior to therapy
Study Arms (1)
Newly diagnosed embryonal tumors
The participants in this study are infants (\< 3 years of age) with newly diagnosed medulloblastoma, primitive neuroectodermal tumor, or other embryonal tumor, atypical teratoid/rhabdoid tumor, intracranial germ cell tumor, or choroid plexus carcinoma who have received no prior therapy with the exception of steroids and have consented to allow research studies on banked tissue specimens
Eligibility Criteria
The participants in this study are infants (\< 3 years of age) with newly diagnosed medulloblastoma, primitive neuroectodermal tumor, or other embryonal tumor, atypical teratoid/rhabdoid tumor, intracranial germ cell tumor, or choroid plexus carcinoma who have received no prior therapy with the exception of steroids and have consented to allow research studies on banked tissue specimens
Contact the study team to discuss eligibility requirements. They can help determine if this study is right for you.
Sponsors & Collaborators
- Pediatric Brain Tumor Consortiumlead
- National Cancer Institute (NCI)collaborator
Study Sites (9)
UCSF Cancer Center and Cancer Research Institute
San Francisco, California, 94143-0128, United States
Children's National Medical Center
Washington D.C., District of Columbia, 20010-2970, United States
Dana-Farber Cancer Institute
Boston, Massachusetts, 02115, United States
Duke Comprehensive Cancer Center
Durham, North Carolina, 27710, United States
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, 19104, United States
Children's Hospital of Pittsburgh
Pittsburgh, Pennsylvania, 15213, United States
Saint Jude Children's Research Hospital
Memphis, Tennessee, 38105-2794, United States
Baylor College of Medicine
Houston, Texas, 77030, United States
Children's Hospital and Regional Medical Center - Seattle
Seattle, Washington, 98105, United States
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY CHAIR
Tobey MacDonald, MD
Children's National Research Institute
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- NETWORK
Study Record Dates
First Submitted
February 2, 2001
First Posted
June 6, 2003
Study Start
March 1, 2001
Primary Completion
March 1, 2003
Study Completion
March 1, 2003
Last Updated
July 20, 2011
Record last verified: 2011-07